ProCE Banner Activity

New Evidence With BTK Inhibitor Therapy in CLL and MCL From SOHO 2023

Conference Coverage
Podcast Episodes

Gain insight into expert perspectives from Catherine C. Coombs, MD, MS, and Toby Eyre, MBChB, MD, as they discuss recent key studies from SOHO 2023 on BTK inhibition in chronic lymphocytic leukemia and mantle cell lymphoma and the potential implications for clinical practice.

Released: October 04, 2023

Share

Faculty

Catherine C. Coombs

Catherine C. Coombs, MD, MS

Associate Clinical Professor of Medicine
Department of Medicine
Divsion of Oncology & Hematology
University of California, Irvine
Irvine, California

Toby A Eyre

Toby A Eyre, MBChB, MD

Hematology Consultant
Honorary Senior Lecturer at the University of Oxford
Oxford University Hospitals NHS Trust
Oxford, United Kingdom

Provided by

Provided by Clinical Care Options

ProCE Banner

Supporters

Supported by an educational grant from Lilly.

Lilly

Disclosure

Primary Author

Catherine C. Coombs, MD, MS

Associate Clinical Professor of Medicine
Department of Medicine
Divsion of Oncology & Hematology
University of California, Irvine
Irvine, California

Catherine C. Coombs, MD, MS: consultant/advisor/speaker: AbbVie, AstraZeneca, Beigene, Genentech, Janssen, LOXO/Lilly, MEI Pharma, Mingsight, Octapharma, TG Therapeutics.

Toby A Eyre, MBChB, MD

Hematology Consultant
Honorary Senior Lecturer at the University of Oxford
Oxford University Hospitals NHS Trust
Oxford, United Kingdom

Toby A. Eyre, MBChB, MD: consultant/advisor/speaker: AbbVie, AstraZeneca, Autolus, BeiGene, Bristol Myers Squibb, Galapagos, Gilead, Incyte, Janssen, Kite, Loxo Oncology, Roche; researcher: AstraZeneca, BeiGene, Gilead.